» Articles » PMID: 33504580

Metabolic Codependencies in the Tumor Microenvironment

Overview
Journal Cancer Discov
Specialty Oncology
Date 2021 Jan 28
PMID 33504580
Citations 135
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This reprogramming is driven by the combined actions of oncogenic alterations in cancer cells and host cell factors acting on cancer cells in the tumor microenvironment. Cancer cell-intrinsic mechanisms activate signal transduction components that either directly enhance metabolic enzyme activity or upregulate transcription factors that in turn increase expression of metabolic regulators. Extrinsic signaling mechanisms involve host-derived factors that further promote and amplify metabolic reprogramming in cancer cells. This review describes intrinsic and extrinsic mechanisms driving cancer metabolism in the tumor microenvironment and how such mechanisms may be targeted therapeutically. SIGNIFICANCE: Cancer cell metabolic reprogramming is a consequence of the converging signals originating from both intrinsic and extrinsic factors. Intrinsic signaling maintains the baseline metabolic state, whereas extrinsic signals fine-tune the metabolic processes based on the availability of metabolites and the requirements of the cells. Therefore, successful targeting of metabolic pathways will require a nuanced approach based on the cancer's genotype, tumor microenvironment composition, and tissue location.

Citing Articles

Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer.

Wu H, Zhang J, Wang Q, Li Z, Li L, Xie Y Sci Rep. 2025; 15(1):6072.

PMID: 39972191 PMC: 11840008. DOI: 10.1038/s41598-025-90963-8.


Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy.

Shao X, Zhao X, Wang B, Fan J, Wang J, An H Theranostics. 2025; 15(5):1689-1714.

PMID: 39897552 PMC: 11780529. DOI: 10.7150/thno.103636.


Exercise-induced extracellular vesicles in reprogramming energy metabolism in cancer.

Puurand M, Llorente A, Line A, Kaambre T Front Oncol. 2025; 14():1480074.

PMID: 39834935 PMC: 11743358. DOI: 10.3389/fonc.2024.1480074.


Fuel for thought: targeting metabolism in lung cancer.

Schneider J, Han S, Nabel C Transl Lung Cancer Res. 2025; 13(12):3692-3717.

PMID: 39830762 PMC: 11736591. DOI: 10.21037/tlcr-24-662.


The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy.

Ma Q, Zhang W, Wu K, Shi L Mol Cancer. 2025; 24(1):14.

PMID: 39806421 PMC: 11727292. DOI: 10.1186/s12943-024-02218-1.


References
1.
Hopkins B, Pauli C, Du X, Wang D, Li X, Wu D . Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018; 560(7719):499-503. PMC: 6197057. DOI: 10.1038/s41586-018-0343-4. View

2.
Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

3.
Bryant K, Stalnecker C, Zeitouni D, Klomp J, Peng S, Tikunov A . Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019; 25(4):628-640. PMC: 6484853. DOI: 10.1038/s41591-019-0368-8. View

4.
Ying H, Dey P, Yao W, Kimmelman A, Draetta G, Maitra A . Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016; 30(4):355-85. PMC: 4762423. DOI: 10.1101/gad.275776.115. View

5.
Ramirez C, Hauser A, Vucic E, Bar-Sagi D . Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis. Nature. 2019; 576(7787):477-481. PMC: 7048194. DOI: 10.1038/s41586-019-1831-x. View